GlassScriptPhysician profile
Richard E Herlihy
NPI 1023070356
$5,480.72
in general payments reported to CMS, 2019-2025
22 companies · $975 in 2025
The $975 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,501 · 2020: $632 · 2021: $431 · 2022: $118 · 2023: $1,723 · 2024: $100 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,546 · Food and Beverage: $1,228 · Education: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,545.84 |
| Food and Beverage | $1,228.27 |
| Education | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,350.70 | 2023 | Aquabeam Robotic System |
| Medtronic, INC. | $1,099.69 | 2022-2025 | Altaviva, Interstim |
| Astellas Pharma US INC | $600.63 | 2019-2021 | |
| Boston Scientific Corporation | $558.48 | 2019-2025 | Axonics |
| Medtronic USA, INC. | $336.30 | 2019 | |
| Coloplast Corp | $299.42 | 2019-2021 | |
| Healthtronics Stone Solutions, LLC | $205.00 | 2021 | |
| Ambu INC. | $175.64 | 2020 | |
| Allergan, INC. | $148.89 | 2019-2020 | |
| Antares Pharma, INC. | $121.50 | 2023 | Xyosted, Tlando |
| Amag Pharmaceuticals, INC. | $121.47 | 2019 | |
| Profound Medical Corp. | $95.74 | 2023 | Tulsa-Pro |
| Accord Healthcare, INC. | $74.76 | 2023-2024 | |
| Abbvie INC. | $70.24 | 2019-2024 | |
| Neotract INC. | $66.66 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $42.87 | 2023 | Bulkamid, Axonics |
| Sumitomo Pharma America, INC. | $23.93 | 2023 | Orgovyx |
| Pfizer INC. | $21.32 | 2023 | |
| Halozyme INC | $20.33 | 2023 | |
| Progenics Pharmaceuticals, INC. | $19.53 | 2024 | |
| Endo Pharmaceuticals INC. | $14.63 | 2019 | |
| Mission Pharmacal Company | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Herlihy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.